RU2634405C2 - Иммуногенная композиция - Google Patents

Иммуногенная композиция Download PDF

Info

Publication number
RU2634405C2
RU2634405C2 RU2014134288A RU2014134288A RU2634405C2 RU 2634405 C2 RU2634405 C2 RU 2634405C2 RU 2014134288 A RU2014134288 A RU 2014134288A RU 2014134288 A RU2014134288 A RU 2014134288A RU 2634405 C2 RU2634405 C2 RU 2634405C2
Authority
RU
Russia
Prior art keywords
conjugate
meningitidis
polysaccharide
saccharide
serogroup
Prior art date
Application number
RU2014134288A
Other languages
English (en)
Russian (ru)
Other versions
RU2014134288A (ru
Inventor
Субхаш Винаяк КАПРЕ
Самбхаджи Шанкер ПИСАЛ
Original Assignee
Серум Инститьют Оф Индия Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Серум Инститьют Оф Индия Лтд. filed Critical Серум Инститьют Оф Индия Лтд.
Publication of RU2014134288A publication Critical patent/RU2014134288A/ru
Application granted granted Critical
Publication of RU2634405C2 publication Critical patent/RU2634405C2/ru

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • A61K2039/627—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
RU2014134288A 2012-01-30 2013-01-29 Иммуногенная композиция RU2634405C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN281MU2012 2012-01-30
IN281/MUM/2012 2012-01-30
PCT/IB2013/050739 WO2013114268A1 (en) 2012-01-30 2013-01-29 Immunogenic composition

Publications (2)

Publication Number Publication Date
RU2014134288A RU2014134288A (ru) 2016-03-20
RU2634405C2 true RU2634405C2 (ru) 2017-10-26

Family

ID=54259032

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2014134288A RU2634405C2 (ru) 2012-01-30 2013-01-29 Иммуногенная композиция

Country Status (17)

Country Link
US (1) US9198977B2 (enExample)
EP (1) EP2809349B1 (enExample)
JP (1) JP6042455B2 (enExample)
KR (1) KR101897317B1 (enExample)
CN (1) CN104302315B (enExample)
BR (1) BR112014018815B1 (enExample)
CA (1) CA2863178C (enExample)
DK (1) DK2809349T3 (enExample)
ES (1) ES2707294T3 (enExample)
HU (1) HUE040914T4 (enExample)
MX (1) MX354103B (enExample)
PT (1) PT2809349T (enExample)
RU (1) RU2634405C2 (enExample)
SG (1) SG11201404447WA (enExample)
SI (1) SI2809349T1 (enExample)
TR (1) TR201900778T4 (enExample)
WO (1) WO2013114268A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2780425C2 (ru) * 2017-01-31 2022-09-23 Пфайзер Инк. Композиции neisseria meningitidis и способы

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE045482T2 (hu) 2005-06-27 2019-12-30 Glaxosmithkline Biologicals Sa Immunogén készítmény
NZ708523A (en) * 2012-11-21 2018-09-28 Serum Institute Of India Pvt Ltd Production of high yields of bacterial polysaccharides
MX365726B (es) 2013-08-24 2019-06-11 Bharat Biotech Int Ltd Vacuna bacteriana y metodos para la fabricacion de la misma.
EP2921856B1 (en) 2014-03-18 2016-09-14 Serum Institute Of India Private Limited A quantitative assay for 4-pyrrolidinopyridine (4-ppy) in polysaccharide-protein conjugate vaccines
US10729780B2 (en) 2015-06-08 2020-08-04 Serum Institute Of India Private Ltd. Methods for improving the adsorption of polysaccharide-protein conjugates and multivalent vaccine formulation obtained thereof
EP3316903A4 (en) * 2015-07-04 2019-01-09 Bharat Biotech International Limited POLYSACCHARIDE VACCINE FORMULATIONS AND METHOD FOR THE INDUSTRIAL MANUFACTURE OF BACTERIAL POLYSACCHARIDES
MX2018010920A (es) * 2016-03-15 2019-03-06 Msd Wellcome Trust Hilleman Laboratories Pvt Ltd Nuevos conjugados de polisacarido-proteina, y procedimiento para obtener los mismos.
CN106110316A (zh) * 2016-06-27 2016-11-16 北京智飞绿竹生物制药有限公司 一种肺炎球菌结合物组合疫苗的制备方法
CN109890413B (zh) * 2016-09-02 2024-04-16 赛诺菲巴斯德股份有限公司 脑膜炎奈瑟氏菌疫苗
CN106397537B (zh) * 2016-10-13 2020-01-07 李红臣 一种高效快速的多糖蛋白结合疫苗纯化分析方法
US11739356B2 (en) * 2017-05-05 2023-08-29 Serum Institute Of India Private Limited Method for removal of impurities from bacterial capsular polysaccharide based preparations
JP2020525495A (ja) * 2017-06-27 2020-08-27 エムエスディー ウェルカム トラスト ヒルマン ラボラトリーズ プライベート リミテッドＭｓｄ Ｗｅｌｌｃｏｍｅ Ｔｒｕｓｔ Ｈｉｌｌｅｍａｎ Ｌａｂｏｒａｔｏｒｉｅｓ Ｐｖｔ．Ｌｔｄ． 新規の多価多糖類・タンパク質のコンジュゲートワクチン組成物及びその製剤
US20200353064A1 (en) * 2018-01-29 2020-11-12 Msd Wellcome Trust Hilleman Laboratories Pvt. Ltd. Novel meningococcal vaccine composition and process thereof
WO2019198096A1 (en) * 2018-04-11 2019-10-17 Msd Wellcome Trust Hilleman Laboratories Pvt. Ltd. Tetravalent meningococcal vaccine composition and process to prepare thereof
JOP20200214A1 (ar) 2019-09-03 2021-03-03 Serum Institute Of India Pvt Ltd تركيبات مولدة للمناعة ضد الأمراض المعوية وطرق لتحضيرها
CA3155669A1 (en) 2019-09-27 2021-04-01 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
US12053515B2 (en) 2020-08-10 2024-08-06 Inventprise, Inc. Multivalent pneumococcal glycoconjugate vaccines containing emerging serotype 24F
CN118078981A (zh) * 2024-04-26 2024-05-28 成都康华生物制品股份有限公司 一种基于双蛋白载体的五价脑膜炎球菌多糖结合疫苗的制备方法及其产品

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080193476A1 (en) * 2005-06-27 2008-08-14 Ralph Leon Biemans Immunogenic Composition
WO2008102173A1 (en) * 2007-02-21 2008-08-28 Health Protection Agency Compositions comprising polysaccharide conjugates and their use as vaccines
RU2378010C2 (ru) * 2003-10-02 2010-01-10 Новартис Вэксинес Энд Дайэгностикс С.Р.Л. Жидкие вакцины для множественных серогрупп менингококков
EP1741442B1 (en) * 2001-06-20 2010-07-21 Novartis Ag Neisseria meningitidis combination vaccines

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2763244B1 (fr) * 1997-05-14 2003-08-01 Pasteur Merieux Serums Vacc Composition vaccinale multivalente a porteur mixte
EP1946769B1 (en) * 2000-06-29 2012-05-30 SmithKline Beecham Biologicals S.A. Multivalent vaccine composition with reduced dose of Haemophilus influenzae type B
GB0130215D0 (en) * 2001-12-18 2002-02-06 Glaxosmithkline Biolog Sa Vaccine
GB0513069D0 (en) * 2005-06-27 2005-08-03 Glaxosmithkline Biolog Sa Immunogenic composition
CN102973929B (zh) * 2005-09-01 2017-04-26 诺华疫苗和诊断有限两合公司 含血清群c脑膜炎球菌的多价疫苗
JP5792920B2 (ja) * 2005-12-22 2015-10-14 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム ワクチン
BR122022002139B1 (pt) * 2009-12-17 2022-08-23 Fina Biosolutions, Llc Processo de conjugação de carboidratos na preparação de vacinas conjugadas e suas respectivas vacinas
EP2852414B9 (en) * 2012-05-22 2020-12-09 GlaxoSmithKline Biologicals SA Meningococcus serogroup x conjugate

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1741442B1 (en) * 2001-06-20 2010-07-21 Novartis Ag Neisseria meningitidis combination vaccines
RU2378010C2 (ru) * 2003-10-02 2010-01-10 Новартис Вэксинес Энд Дайэгностикс С.Р.Л. Жидкие вакцины для множественных серогрупп менингококков
US20080193476A1 (en) * 2005-06-27 2008-08-14 Ralph Leon Biemans Immunogenic Composition
WO2008102173A1 (en) * 2007-02-21 2008-08-28 Health Protection Agency Compositions comprising polysaccharide conjugates and their use as vaccines

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2780425C2 (ru) * 2017-01-31 2022-09-23 Пфайзер Инк. Композиции neisseria meningitidis и способы
RU2839906C1 (ru) * 2019-09-27 2025-05-13 Пфайзер Инк. Композиции с Neisseria meningitidis и способы их применения
RU2839906C9 (ru) * 2019-09-27 2025-06-23 Пфайзер Инк. Композиции с Neisseria meningitidis и способы их применения

Also Published As

Publication number Publication date
BR112014018815A2 (enExample) 2017-06-20
SG11201404447WA (en) 2014-08-28
CA2863178C (en) 2021-04-06
US20140377302A1 (en) 2014-12-25
WO2013114268A1 (en) 2013-08-08
EP2809349A1 (en) 2014-12-10
CN104302315A (zh) 2015-01-21
RU2014134288A (ru) 2016-03-20
CA2863178A1 (en) 2013-08-08
JP6042455B2 (ja) 2016-12-14
SI2809349T1 (sl) 2019-03-29
KR20140123553A (ko) 2014-10-22
ES2707294T3 (es) 2019-04-03
HUE040914T4 (hu) 2019-05-28
MX354103B (es) 2018-02-13
KR101897317B1 (ko) 2018-09-11
BR112014018815A8 (pt) 2017-07-11
US9198977B2 (en) 2015-12-01
EP2809349A4 (en) 2015-08-26
EP2809349B1 (en) 2018-12-19
DK2809349T3 (da) 2019-02-18
PT2809349T (pt) 2019-02-01
MX2014009250A (es) 2015-03-19
TR201900778T4 (tr) 2019-02-21
BR112014018815B1 (pt) 2022-07-12
CN104302315B (zh) 2018-02-06
JP2015509111A (ja) 2015-03-26

Similar Documents

Publication Publication Date Title
US9198977B2 (en) Immunogenic composition
US20220143167A1 (en) Saccharide-polypeptide conjugate compositions and methods of use thereof
AU2007284878B2 (en) Protein matrix vaccines and methods of making and administering such vaccines
US20250262290A1 (en) Saccharide-polypeptide conjugate compositions and methods of use thereof
KR20160005793A (ko) 담체 단백질에 대한 박테리아 다당류의 컨쥬게이션 방법
IE58977B1 (en) Covalently-modified neutral bacterial polysaccharides, stable covalent conjugates of such plysaccharides and immunogenic proteins, and methods of preparing such polysaccharides and conjugates
US20120231086A1 (en) Protein matrix vaccines of improved immunogenicity
US12053515B2 (en) Multivalent pneumococcal glycoconjugate vaccines containing emerging serotype 24F
WO2020157772A1 (en) Multivalent pneumococcal polysaccharide-protein conjugate vaccine compositions
WO2017011338A1 (en) Sortase-mediated coupling of immunogenic polysaccharide-protein conjugates and their use
BE1024282B1 (fr) Compositions immunogènes
Zou et al. Preparation of glycoconjugate vaccines
US11246918B2 (en) Haemophilus influenzae saccharide-carrier conjugate compositions and uses thereof
Moingeon Challenges and Opportunities in the Development of New Conjugate Vaccines against Infectious Diseases
안소정 Development of efficient Vi polysaccharide conjugate vaccine and its vaccination strategy for prevention of typhoid fever

Legal Events

Date Code Title Description
PD4A Correction of name of patent owner